- £1.11bn
- £1.13bn
- £299.40m
- 80
- 35
- 50
- 55
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 288 | 265 | 311 | 338 | 299 |
Cost of Revenue | |||||
Gross Profit | 176 | 142 | 165 | 175 | 163 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 184 | 201 | 218 | 250 | 226 |
Operating Profit | 104 | 64 | 93.4 | 88.5 | 73.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 105 | 63.5 | 92.5 | 87.7 | 72.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 92.4 | 54.2 | 72.8 | 75.5 | 61 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 92.4 | 54.2 | 73.2 | 76.2 | 61.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 92.4 | 54.2 | 73.2 | 76.2 | 61.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.09 | 0.751 | 0.832 | 0.947 | 0.775 |
Dividends per Share | |||||
Special Dividends per Share |